BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter?

Proto‐oncogene B‐Raf (BRAF) mutation rates have been reported in nevi and melanomas of homogeneous Caucasian cohorts.

[1]  Yasser Heakal,et al.  Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma , 2011, The Annals of pharmacotherapy.

[2]  D. Schadendorf,et al.  Genetic and morphologic features for melanoma classification , 2010, Pigment cell & melanoma research.

[3]  Michael R. Green,et al.  Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions? , 2010, Human pathology.

[4]  R. Zeillinger,et al.  Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. , 2009, The Journal of molecular diagnostics : JMD.

[5]  Jane Fridlyand,et al.  Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.

[6]  Michael R. Green,et al.  Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7 , 2008, Cell.

[7]  L. Akslen,et al.  Mutation analysis of the EGFR–NRAS–BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma , 2008, Melanoma research.

[8]  W. Westra,et al.  Distribution of BRAF T1799A(V600E) Mutations Across Various Types of Benign Nevi: Implications for Melanocytic Tumorigenesis , 2007, The American Journal of dermatopathology.

[9]  M. Trivett,et al.  Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.

[10]  T. Saida,et al.  High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. , 2006, The Journal of investigative dermatology.

[11]  Stephen B Gruber,et al.  BRAF and NRAS mutations in melanoma and melanocytic nevi , 2006, Melanoma research.

[12]  N. Thomas.  BRAF somatic mutations in malignant melanoma and melanocytic naevi , 2006, Melanoma research.

[13]  T. Papp,et al.  Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi , 2005, Melanoma research.

[14]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. , 2005, European journal of cancer.

[15]  C. Garbe,et al.  Risk factors of incident melanocytic nevi: A longitudinal study in a cohort of 1,232 young German children , 2005, International journal of cancer.

[16]  F. Barany,et al.  Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction , 2005, Journal of cutaneous pathology.

[17]  M. Hussein,et al.  Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues , 2005, Journal of Clinical Pathology.

[18]  Christopher J. Miller,et al.  Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. , 2004, The Journal of investigative dermatology.

[19]  Kazuhiro Takahashi,et al.  BRAF point mutations in primary melanoma show different prevalences by subtype. , 2004, The Journal of investigative dermatology.

[20]  Ajay N. Jain,et al.  Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.

[21]  M. Flaig,et al.  Mutations of the BRAF gene in benign and malignant melanocytic lesions. , 2003, The Journal of investigative dermatology.

[22]  I. Wistuba,et al.  BRAF Mutation: A Frequent Event in Benign, Atypical, and Malignant Melanocytic Lesions of the Skin , 2003, The American Journal of dermatopathology.

[23]  M. Arumí-Uría,et al.  Grading of Atypia in Nevi: Correlation with Melanoma Risk , 2003, Modern Pathology.

[24]  D. Bennett.  Human melanocyte senescence and melanoma susceptibility genes , 2003, Oncogene.

[25]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[26]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[27]  A. Sarasin,et al.  The molecular pathways of ultraviolet-induced carcinogenesis. , 1999, Mutation research.

[28]  R. Vollmer,et al.  Correlating architectural disorder and cytologic atypia in Clark (dysplastic) melanocytic nevi. , 1999, Human pathology.

[29]  J. Mark Elwood,et al.  Melanoma and sun exposure: An overview of published studies , 1997, International journal of cancer.

[30]  A Halpern,et al.  Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. , 1997, JAMA.

[31]  D. Elder,et al.  Dysplastic nevi and other risk markers for melanoma. , 1996, Seminars in oncology.

[32]  N. Hayward,et al.  Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. , 1996, The American journal of pathology.

[33]  J. A. Bishop,et al.  Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. , 1996, British Journal of Cancer.

[34]  A. Sober,et al.  Precursors to skin cancer , 1995, Cancer.

[35]  A. Halpern,et al.  Dysplastic nevi as a melanoma risk factor in patients with familial melanoma , 1994, Cancer.

[36]  A. Marghoob,et al.  Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome. A case-control study. , 1994, Archives of dermatology.

[37]  W. Pierceall,et al.  N-ras mutation in ultraviolet radiation-induced murine skin cancers. , 1992, Cancer research.

[38]  A. Halpern,et al.  Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. , 1991, Archives of dermatology.

[39]  W. Clark,et al.  Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. , 1978, Archives of dermatology.

[40]  B. Mayer,et al.  A Climatology of UV Radiation, 1979–2000, 65S–65N , 2010 .

[41]  Daniel L. Schmoldt,et al.  UV radiation in global climate change : measurements, modeling and effects on ecosystems , 2010 .

[42]  P. Uribe,et al.  Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. , 2006, The Journal of investigative dermatology.

[43]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[44]  M. Kotze,et al.  A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. , 2000, Genetic testing.

[45]  T. Mack,et al.  The pathogenesis of melanoma induced by ultraviolet radiation. , 1999, The New England journal of medicine.

[46]  W. Clark,et al.  Problems with lesions related to the development of malignant melanoma: common nevi, dysplastic nevi, malignant melanoma in situ, and radial growth phase malignant melanoma. , 1998, Human pathology.

[47]  A. Sober,et al.  Ultraviolet radiation and malignant melanoma. , 1998, Clinics in dermatology.

[48]  J. Bos,et al.  Activation of N-ras induced by ultraviolet irradiation in vitro. , 1988, Oncogene research.